11:52 AM EST - Cangene Corp. : said on Friday that it has been advised by the Biomedical Advanced Research and Development Authority that Cangene has been eliminated from the competitive range with respect to its bid on a contract for developing a treatment for acute radiation syndrome. Cangene had originally submitted a response to a request for proposal for a development and supply contract for an ARS treatment that was issued by the Authority in 2008, and had anticipated a possible contract award later that year. Cangene Corp.
shares T.CNJ are trading up $0.04 at $3.64.
